All In Biotech

Drug Trial Radar · NCT06627179

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Dec 11, 2024

Primary completion

Jul 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Laboratoires TheaIndustry
Sponsor type
Industry
Collaborators
Sepul Bio
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.

Conditions

  • Retinitis Pigmentosa (RP)
  • Usher Syndrome Type 2
  • Deaf Blind
  • Retinal Disease
  • Eye Diseases, Hereditary
  • Eye Disorders Congenital
  • Vision Disorders

Interventions

  • Intravitreal Injection of UltevursenDrug

    Up to 4 doses over a 24-month period

  • No intervention, will not receive any active study interventionOther

    Sham-procedure (no experimental drug administered)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate efficacy after 24 months of treatmentTime frame: 24 Months

Locations

26 sites in 10 countries. Site status is shown where the registry gives one.

  • The University of California, San Francisco

    San Francisco, California

  • Bascom Palmer Eye Institute/University of Miami

    Miami, Florida

  • Emory University

    Atlanta, Georgia

  • Massachusetts Eye and Ear

    Boston, Massachusetts

  • University of Michigan- Kellogg Eye Center

    Ann Arbor, Michigan

  • Casey Eye Institute, Oregon Health & Science University

    Portland, Oregon

  • University of Pennsylvania, Scheie Eye Institute

    Philadelphia, Pennsylvania

  • Retina Foundation of the Southwest

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • University of Wisconsin- Madison

    Madison, Wisconsin

  • Ghent University Hospital

    Ghent, Belgium

  • INRET Clínica/ Santa Casa de Misericórdia de Belo Horizonte

    Belo Horizonte, Brazil

  • Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP)

    São Paulo, Brazil

  • Hospital for Sick Children

    Toronto, Ontario, Canada

  • McGill University Health Centre for Innovative Medicine

    Montreal, Quebec, Canada

  • Rigshospitalet and University of Copenhagen

    Glostrup Municipality, Denmark

  • Hôpital Gui de Chauliac - CHRU de Montpellier - Maladies Sensorielles Génétique

    Montpellier, France

  • Centre de maladies rares CHNO des Quinze Vingt

    Paris, France

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • ASST Santi Paolo e Carlo Hospital, University of Milan

    Milan, Italy

  • Amsterdam University Medical Center - Locatie AMC

    Amsterdam, Netherlands

  • Radboud Universitair Medisch Centrum

    Nijmegen, Netherlands

  • Het Oogziekenhuis Rotterdam

    Rotterdam, Netherlands

  • University of Edinburgh / NHS Lothian

    Edinburgh, United Kingdom

  • Moorfields Eye Hosptial

    London, United Kingdom

  • Oxford Eye Hospital

    Headington, Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.